OSE Immunotherapeutics

OSE · Euronext Paris

Public Market Listing

OSEEuronext Paris

Euronext Paris primary exchange listing

Live quotes, historical charts, and market capitalization for OSE Immunotherapeutics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
Tumor-associated antigensVaccine
Non-Small Cell Lung Cancer
Phase 1/2
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
OSE2101Phase 3Patients With Non-Small Cell Lung Cancer
Est. primary completion 2028-05-01 · NCT06472245 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
OSE2101 + OSE-279Phase 1/2Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
Est. primary completion 2029-12 · NCT05751798 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026Topline resultOSE2101Phase 2 Combi-TED (NCT04884282) of Tedopi combinations in NSCLC met its primary endpoint
OSE Immunotherapeutics · Source ↗
22 May 2026Topline resultOSE2101TEDOVA (NCT04713514) Phase 2 met its primary endpoint
OSE Immunotherapeutics SA (trial sponsored by ARCAGY-GINECO) · Source ↗

Financial reports

No financial reports recorded.